Key result
Cost-effectiveness comparisons between Cardioform and Amplatzer devices for patent foramen ovale closure raise concerns regarding methodological transparency and interpretation of clinical results.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Not only is the statement of improved clinical outcomes unsupported by the underlying clinical evidence, but there is also no mention of uncertainty in the cost-effectiveness results discussed in the key concluding statements.”
This article raises methodological concerns regarding a previously published cost-effectiveness analysis of Cardioform versus Amplatzer devices for PFO closure.
Volpi et al. recently published an article evaluating the cost-effectiveness of patent foramen ovale (PFO) management strategies, comparing closure with the Cardioform vs. Amplatzer device for seco...
No takes yet. Share an insight, caveat, or question.
Hutton et al. (2026) studied this question. Cost-effectiveness comparisons between Cardioform and Amplatzer devices for patent foramen ovale closure raise concerns regarding methodological transparency and interpretation of clinical results.
Synapse has enriched 10 related papers. Consider them for comparative context: